{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import openai\n",
    "import json\n",
    "import pandas as pd\n",
    "from transformers import GPT2TokenizerFast"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "openai.organization = \"org-iKrZv1G3h27ngg6tO3rkCDlk\"\n",
    "# openai.api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "openai.api_key = \"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\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "tokenizer = GPT2TokenizerFast.from_pretrained(\"gpt2\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('trial1_string.txt', encoding='utf8') as f:\n",
    "    text = f.readlines()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "['Non-Interventional Study Protocol\\n',\n",
       " 'Study Short Title\\n',\n",
       " 'Evaluation of the sensitivity and specificity of a novel quality of life (QoL)\\n',\n",
       " 'tool to assess the treatment satisfaction in psoriasis patients\\n',\n",
       " 'STUDY IDENTIFICATION No. 2020-A00652-37\\n',\n",
       " 'Full Study Title\\n',\n",
       " 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel\\n',\n",
       " 'QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) among moderate to\\n',\n",
       " 'severe psoriasis patients treated with brodalumab (Kyntheum®)\\n',\n",
       " 'GPP statement: This Non-Interventional Study will be conducted in compliance with the\\n',\n",
       " 'Clinical Study Protocol, Good Pharmacoepidemiology Practices and\\n',\n",
       " 'applicable regulatory requirement(s).\\n',\n",
       " 'Sponsoring entity:\\n',\n",
       " 'LEO Pharma France\\n',\n",
       " 'LEO Study ID: PSO-TARGET\\n',\n",
       " '2 rue René Caudron\\n',\n",
       " '215 avenue Georges Clemenceau\\n',\n",
       " '78960 Voisins-Le-Bretonneux\\n',\n",
       " 'Date: 25-05-2020\\n',\n",
       " 'Version: 2.0\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 2 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'KEY STUDY PERSONNEL\\n',\n",
       " 'STUDY MANAGER\\n',\n",
       " 'BERTRAND Bénédicte, Clinical Manager\\n',\n",
       " 'CLINACT\\n',\n",
       " 'Vélizy Espace – Immeuble Santos Dumont\\n',\n",
       " '13 avenue Morane Saulnier – CS 50730\\n',\n",
       " '78457 Vélizy-Villacoublay Cedex, France\\n',\n",
       " 'MAIN PROTOCOL AUTHOR\\n',\n",
       " 'SALTET DE SABLET Thibaut, Medical Writer\\n',\n",
       " 'CLINACT\\n',\n",
       " 'Vélizy Espace – Immeuble Santos Dumont\\n',\n",
       " '13 avenue Morane Saulnier – CS 50730\\n',\n",
       " '78457 Vélizy-Villacoublay Cedex, France\\n',\n",
       " 'STATISTICIAN\\n',\n",
       " 'CARRERE Florence, Head of Biometry /\\n',\n",
       " 'Senior Biostatistician\\n',\n",
       " 'STATITEC\\n',\n",
       " 'Vélizy Espace – Immeuble Santos Dumont\\n',\n",
       " '13 avenue Morane Saulnier – CS 50730\\n',\n",
       " '78457 Vélizy-Villacoublay Cedex, France\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 3 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'APPROVERS\\n',\n",
       " 'The following person(s) within LEO Pharma (LEO) has/have approved this Study Protocol by\\n',\n",
       " 'signing the Non-Interventional Study Protocol Approval Form adjoined as a separate page to\\n',\n",
       " 'this document:\\n',\n",
       " 'Nadine MacKenzie\\n',\n",
       " 'Medical director, France and Benelux\\n',\n",
       " 'Sarah Moumane\\n',\n",
       " 'Dermatology MSL manager, France\\n',\n",
       " 'Angèle GUILBOT\\n',\n",
       " 'Scientific and Regulatory Director\\n',\n",
       " 'CLINACT\\n',\n",
       " 'Vélizy Espace – Immeuble Santos Dumont\\n',\n",
       " '13 avenue Morane Saulnier – CS 50730\\n',\n",
       " '78457 Vélizy-Villacoublay Cedex, France\\n',\n",
       " 'Dr Ziad REGUIAI\\n',\n",
       " 'International Co-ordinating Investigator\\n',\n",
       " 'Polyclinique Reims-Bezannes\\n',\n",
       " '89 Rue Victor De Broglie\\n',\n",
       " '51430 Bezannes, FRANCE\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 4 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '1 Table of Contents\\n',\n",
       " '1 Table of Contents ................................................................................................................... 4\\n',\n",
       " '2 List of Abbreviations .............................................................................................................. 7\\n',\n",
       " '3 Responsible Parties ................................................................................................................ 8\\n',\n",
       " '4 Abstract ................................................................................................................................ 10\\n',\n",
       " '5 Amendments and Updates .................................................................................................. 15\\n',\n",
       " '6 Milestones ........................................................................................................................... 16\\n',\n",
       " '7 Rationale and Background ................................................................................................... 16\\n',\n",
       " '8 Research Question and Objectives ...................................................................................... 20\\n',\n",
       " 'Primary Objective ............................................................................................................ 20\\n',\n",
       " 'Secondary Objectives ...................................................................................................... 20\\n',\n",
       " '9 Research Method................................................................................................................. 20\\n',\n",
       " 'Study Design .................................................................................................................... 20\\n',\n",
       " 'Eligibility criteria .......................................................................................................... 20\\n',\n",
       " 'PSO-TARGET Quality of Life Component grid. ............................................................. 21\\n',\n",
       " 'Dermatology Quality of Life Index (DLQI) .................................................................... 22\\n',\n",
       " 'Limitation of bias ......................................................................................................... 23\\n',\n",
       " 'Study Schedule ............................................................................................................ 23\\n',\n",
       " 'Definition of a non-interventional study ..................................................................... 24\\n',\n",
       " 'Setting .............................................................................................................................. 25\\n',\n",
       " 'Variables .......................................................................................................................... 26\\n',\n",
       " 'Data Source ..................................................................................................................... 28\\n',\n",
       " 'Study Size ......................................................................................................................... 29\\n',\n",
       " 'Data Management ........................................................................................................... 30\\n',\n",
       " 'Data Analysis ................................................................................................................... 32\\n',\n",
       " 'Statistical Analysis Plan.................................................................................................... 32\\n',\n",
       " 'Description of the population ..................................................................................... 32\\n',\n",
       " 'Baseline characteristics ............................................................................................... 33\\n',\n",
       " 'Sensitivity/sensibility analysis ..................................................................................... 33\\n',\n",
       " 'Efficacy analysis ........................................................................................................... 35\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 5 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Other secondary analyses ........................................................................................... 36\\n',\n",
       " 'Safety analysis ............................................................................................................. 39\\n',\n",
       " 'Quality Control ................................................................................................................ 39\\n',\n",
       " 'Data Collection ............................................................................................................ 39\\n',\n",
       " 'Data monitoring........................................................................................................... 39\\n',\n",
       " 'Data validation............................................................................................................. 40\\n',\n",
       " 'Limitations of Research Methods .................................................................................... 40\\n',\n",
       " 'Other Aspects .................................................................................................................. 41\\n',\n",
       " '10 Protection of human subjects ............................................................................................. 41\\n',\n",
       " '11 Management and Reporting of Adverse Events and Other Experiences ............................ 44\\n',\n",
       " 'Definitions ....................................................................................................................... 44\\n',\n",
       " 'Physician’s responsibility for reporting of Adverse Drug Reactions, Adverse Events and\\n',\n",
       " 'Other Experiences ........................................................................................................... 45\\n',\n",
       " 'LEO responsibilities for reporting of safety-related data ................................................ 47\\n',\n",
       " '12 Plans for Disseminating and Communicating Study Results ............................................... 47\\n',\n",
       " '13 References ........................................................................................................................... 48\\n',\n",
       " 'Annex 1. PSO-TARGET Component Grid ................................................................................... 51\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 6 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'APPENDICES\\n',\n",
       " '1. PSO-TARGET Component grid\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 7 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '2 List of Abbreviations\\n',\n",
       " 'ADR: Adverse Drug Reaction\\n',\n",
       " 'AE: Adverse Event\\n',\n",
       " 'CRF: Case Report Form\\n',\n",
       " 'CRO: Contract Research Organization\\n',\n",
       " 'DLQI: Dermatology Quality of Life Index\\n',\n",
       " 'HCP: Healthcare Practitioner\\n',\n",
       " 'IEC: Independent Ethics Committee\\n',\n",
       " 'IRB: Institutional Review Board\\n',\n",
       " 'LEO LEO Pharma A/S and/or affiliates or representatives\\n',\n",
       " 'MedDRA: Medical dictionary for Regulatory Activities\\n',\n",
       " 'NIS: Non-Interventional Study\\n',\n",
       " 'OE: Other Experience\\n',\n",
       " 'PASI: Psoriasis Area and Severity Index\\n',\n",
       " 'PRO: Patient Reported Outcome\\n',\n",
       " 'QoL: Quality of Life\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 8 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '3 Responsible Parties\\n',\n",
       " 'Sponsor : LEO pharma France\\n',\n",
       " '2 Rue René Caudron\\n',\n",
       " '78960 Voisins-le-Bretonneux\\n',\n",
       " 'France\\n',\n",
       " 'Study Sponsor Contact: Yassmina Mandouri\\n',\n",
       " '2 Rue René Caudron,\\n',\n",
       " '78960 Voisins-le-Bretonneux\\n',\n",
       " 'Email yamfr @leo-pharma.com\\n',\n",
       " 'Contract Research Organization: CLINACT\\n',\n",
       " 'Vélizy Espace, bâtiment Santos Dumont\\n',\n",
       " '13 Avenue Morane Saulnier\\n',\n",
       " '78140 Vélizy-Villacoublay\\n',\n",
       " 'Coordinating Investigator:\\n',\n",
       " 'Dr Ziad REGUIAI\\n',\n",
       " 'Polyclinique Reims-Bezannes\\n',\n",
       " '89 Rue Victor De Broglie\\n',\n",
       " '51430 Bezannes, FRANCE\\n',\n",
       " 'Scientific committee:\\n',\n",
       " 'Dr Pierre-Dominique GHISLAIN\\n',\n",
       " 'Cliniques Universitaires Saint Luc – Université Catholique de Louvain\\n',\n",
       " 'Avenue Hippocrate 10,\\n',\n",
       " '1200 Woluwe- Saint-Lambert\\n',\n",
       " 'Dr Thierry BOYE\\n',\n",
       " \"Hôpital d'Instruction des armées SAINTE ANNE (TOULON)\\n\",\n",
       " 'BCRM TOULON 2 boulevard Sainte Anne BP 600 – 83800 TOULON Cedex 9\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 9 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Dr Ziad REGUIAI\\n',\n",
       " 'Polyclinique Reims-Bezannes\\n',\n",
       " '89 Rue Victor De Broglie\\n',\n",
       " '51430 Bezannes, France\\n',\n",
       " 'LEO Pharma legal entity is the sponsor of the study and the Contract Research Organisation(s)\\n',\n",
       " '(CRO) CLINACT is authorised by LEO to act on behalf of LEO. LEO Pharma 2 Rue René Caudron,\\n',\n",
       " '78960 Voisins-le-Bretonneux, France will be the Data Controller.\\n',\n",
       " 'Contact and responsibilities of all parties contributing to the study, including all investigators,\\n',\n",
       " 'are detailed in a stand-alone document available upon request to LEO. For key contributors,\\n',\n",
       " 'e.g. national coordinating investigators, LEO will keep CVs and documentation regarding\\n',\n",
       " 'Conflicts of Interest and make such documentation available upon request from relevant\\n',\n",
       " 'parties, e.g. authorities, journals. LEO will keep a record of all relevant sponsor personnel.\\n',\n",
       " 'CLINACT will keep a record of all involved CRO personnel.\\n',\n",
       " 'The following essential documents must be in the hands of LEO before the study is initiated at\\n',\n",
       " 'a site:\\n',\n",
       " '\\uf0b7 Written agreement between LEO or CLINACT and the Study Site Responsible / Clinic /\\n',\n",
       " 'Hospital.\\n',\n",
       " '\\uf0b7 Signed and dated protocol agreement and amendment agreements, if any, with the\\n',\n",
       " 'original signature of the Site Responsible.\\n',\n",
       " '\\uf0b7 Patient Information Sheet and Informed Consent Form in local language (notified to /\\n',\n",
       " 'approved by Independent Ethics Committees (IECs).\\n',\n",
       " '\\uf0b7 Written IEC / IRB approval.\\n',\n",
       " '\\uf0b7 Competent Authority notification.\\n',\n",
       " '\\uf0b7 Product liability insurance.\\n',\n",
       " '\\uf0b7 LEO safety plan which is a three party agreement between Global safety, Safety contact\\n',\n",
       " 'person and the CRO on the handling of safety reporting\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 10 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '4 Abstract\\n',\n",
       " 'Title\\n',\n",
       " 'Evaluation of the sensitivity and specificity, compared to DLQI as a standard tool, of a novel\\n',\n",
       " 'QOL questionnaire (treat to the Patient satiSfactiOn TARGET in Psoriasis patients) among\\n',\n",
       " 'moderate to severe psoriasis patients treated with brodalumab (Kyntheum®)\\n',\n",
       " 'Rationale and background\\n',\n",
       " 'The severity of psoriasis can be influenced by a great variety of factors including extent of the\\n',\n",
       " 'disease, lesions location and impact on quality of life. The current standard of care for psoriasis\\n',\n",
       " 'is focusing on the reduction of the skin symptoms as defined by the PASI, somewhat setting\\n',\n",
       " 'asides the patient’s feelings in terms of which aspects of his/her life are affected by the\\n',\n",
       " 'disease. Despite the fact that multiple patient reported outcomes (PRO) questionnaires are\\n',\n",
       " 'available to evaluate the impact of the disease on patients’ quality of life, only few items\\n',\n",
       " 'address the subjective impact of skin disease. Among the available PROs the Dermatology Life\\n',\n",
       " 'Quality Index (DLQI) is the most frequently used. It is a standardized tool designed to cover a\\n',\n",
       " 'broad range of dermatologic afflictions but lacks specificity towards the effect of psoriasis on\\n',\n",
       " 'quality of life. The DLQI is composed of ten questions grouped in 6 domains “symptoms and\\n',\n",
       " 'feelings”, “daily activities”, “leisure”, “work/school”, “personal relationships” and “treatment”.\\n',\n",
       " 'Each answer is graded from 0 to 3. The DLQI score is calculated by adding the score of each\\n',\n",
       " 'question, resulting in a maximum score of 30 and a minimum of 0. The higher the score, the\\n',\n",
       " \"more quality of life is impaired. A score higher than 10 indicates that the patient's life is being\\n\",\n",
       " 'severely affected by their skin disease.\\n',\n",
       " 'Because of its limitations, some patients cannot seem to completely restore a normal quality\\n',\n",
       " 'of life (e.g. DLQI 0-1) even though their reached a perfect PASI score (100). This phenomenon\\n',\n",
       " 'may be explained by the fact that the patient’s own perception can be different from the\\n',\n",
       " 'physician’s perspective and may have changed in time, between follow-ups. These are as many\\n',\n",
       " 'reasons as why it is highly difficult to accurately fathom the therapeutic expectations of the\\n',\n",
       " 'psoriasis patients. The standard tools currently in use are not able to assess the perception of\\n',\n",
       " 'the disease by the patient its evolution over time. In addition, it is widely recognized that\\n',\n",
       " 'alexithymia is more prevalent in the psoriasis patients than in the general population and\\n',\n",
       " 'patients with alexithymia appear to suffer higher psoriasis burden as they have more\\n',\n",
       " 'difficulties to express their expectations. Since patients struggle to recognize and verbalize\\n',\n",
       " 'their emotions, it can be useful and informative to offer patients a variety of verbatim in which\\n',\n",
       " '\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 11 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'they can identify. PSO-TARGET is an exploratory observational, non-interventional study\\n',\n",
       " 'aiming to evaluate a novel approach of assessing psoriasis patients’ satisfaction towards their\\n',\n",
       " 'biologic treatment from a quality of life standpoint by using a psoriasis-specific Quality of Life\\n',\n",
       " 'assessment grid.\\n',\n",
       " 'Research question and objectives\\n',\n",
       " 'The aim of this exploratory study is to evaluate the sensitivity and specifity of the PSO-\\n',\n",
       " 'TARGET QoL Component grid as part of a new approach for assessing the level of achievement\\n',\n",
       " 'of the psoriasis patient’s therapeutic goal, identified by himself, after a treatment with\\n',\n",
       " 'Kyntheum®. This tool will be, if validated, used by physicians to devise a “Treat to patient\\n',\n",
       " 'satisfaction target” strategy that better suits their patients’ expectations.\\n',\n",
       " 'To construct this new questionnaire, the first step was to collect psoriasis patients’\\n',\n",
       " 'feedback on what is the aspect of their life that is the most impacted by the disease and which\\n',\n",
       " 'is the one they would want to improve the most. To this aim, a retrospective survey based on\\n',\n",
       " 'the recollection and experience from three clinical dermatologists (two French and one\\n',\n",
       " 'Belgian) of patient’s expectations, has been conducted. The results of the survey have been\\n',\n",
       " 'used to analyse the type of expectations provided by the patients. Based on that analysis, the\\n',\n",
       " 'expert dermatologists generated a grid containing 12 therapeutic goals equally distributed into\\n',\n",
       " 'the four major psychometric components classically used in quality of life studies in patients\\n',\n",
       " 'with chronic diseases (physical, subjective, relational/social and therapeutic). The proposed\\n',\n",
       " 'verbatim was then reviewed by a psychologist to ensure that there was a balance between the\\n',\n",
       " 'proposals; i.e. the vocabulary used was neutral enough not to guide the choices. This first step\\n',\n",
       " 'has therefore given rise to a QoL component grid that will be administered to the patients\\n',\n",
       " 'prior to the initiation of a systemic treatment (Kyntheum® / brodalumab) to set up a main\\n',\n",
       " 'objective for the upcoming treatment. At 12-16 weeks the patient will be asked to rate his/her\\n',\n",
       " 'level of satisfaction in regard to the treatment objective defined prior to treatment initiation\\n',\n",
       " 'using a four-point Likert scale (“very satisfied”, “satisfied”, “unsatisfied”, “very unsatisfied”). In\\n',\n",
       " 'order to evaluate the sensitivity and specificity of, the PSO-TARGET QoL component grid, the\\n',\n",
       " 'patient will be asked to fill in, prior the treatment introduction and during the follow up visits,\\n',\n",
       " 'the DLQI questionnaire. The primary objective of the study will be to estimate the level of\\n',\n",
       " 'concordance of this satisfaction level based on the PSO-TARGET QOL tool and the reference\\n',\n",
       " 'method in Quality of Life for psoriasis patients; i.e. the DLQI, at the same time point. This aim\\n',\n",
       " 'will be reached by comparing, at 12-16 weeks, the DLQI and the satisfaction level given by\\n',\n",
       " 'patients in regard to their own treatment objective defined at baseline using the PSO-TARGET\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 12 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'QoL component grid. True Positive (TP), False Positive (FP), True Negative (TN) and False\\n',\n",
       " 'Negative (FN) will be defined using a contingency table. These quantitative variables will be\\n',\n",
       " 'used to calculate the sensitivity (proportion of actual satisfied patients that are correctly\\n',\n",
       " 'identified as such) and specificity (proportion of actual unsatisfied patients that are correctly\\n',\n",
       " 'identified as such) of the PSO-TARGET QoL Component grid, compared to the quality of life\\n',\n",
       " 'given by the DLQI. If these metrics reach a certain threshold (85%), the PSO-TARGET QoL\\n',\n",
       " 'component grid will be considered for additional studies in order to validate it at a larger scale\\n',\n",
       " 'and further demonstrate it is as much sound in assessing the patients’ quality of life as the\\n',\n",
       " 'DLQI.\\n',\n",
       " 'Because of the fact that alexithymia is highly prevalent in psoriasis patients, the grid will\\n',\n",
       " 'be administered to the patient after he/she had spontaneously expressed his/her treatment\\n',\n",
       " 'expectations. This should help the patient to narrow down the specific goal where his/her\\n',\n",
       " 'expectation belongs. In addition, as part of a secondary objective the treating physician will\\n',\n",
       " 'also choose an item from the table based on what he/she perceives in terms of patient’s\\n',\n",
       " 'expectations without disclosing it to the patient. This will allow us to evaluate the level of\\n',\n",
       " 'accordance between the physician-chosen and the patient-chosen therapeutic goal. As\\n',\n",
       " 'another secondary endpoint, the level of achievement of the therapeutic goal will be assessed\\n',\n",
       " 'at 12/16 weeks and followed-up for 52 ± 4 weeks. Patients scoring the treatment as “satisfied\\n',\n",
       " 'or very satisfied” will be considered as having achieved their therapeutic goal. Another\\n',\n",
       " 'endpoint of interest (secondary) will be to assess, after 12/16 weeks of treatment, if the\\n',\n",
       " 'patient chooses a new therapeutic goal, different from the one he initially defined.\\n',\n",
       " 'It is important to note that, this study being observational, none of the visits (baseline\\n',\n",
       " 'and follow-ups) are specific to the trial but part of the dermatologists’ standard of care in both\\n',\n",
       " 'countries (France and Belgium). In addition, in order to limit variability in terms of treatment\\n',\n",
       " 'profiles (dosage and administration schedule) and thus to keep the study population as\\n',\n",
       " 'homogenous as possible, it has been decided to include only patients treated by Kyntheum®,\\n',\n",
       " 'in other terms Kyntheum® treatment is an accessory to the study but PSO-TARGET will not\\n',\n",
       " 'assess Kyntheum® efficacy per se.\\n',\n",
       " 'The study objectives are the following:\\n',\n",
       " 'Primary objective:\\n',\n",
       " 'Assess at week 12/16, post biologic treatment, the sensitivity and the specificity, compared to\\n',\n",
       " 'DLQI as a standard tool, of the PSO-TARGET QoL component grid as a novel approach aiming\\n',\n",
       " 'to evaluate the patients’ satisfaction with regard of their treatment.\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 13 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Secondary objectives:\\n',\n",
       " '- Evaluate at week 12/16, post Kyntheum® treatment, the percentage of patients who has\\n',\n",
       " 'achieved the main treatment goal they identified in the QoL component grid at baseline.\\n',\n",
       " '- Identification of predictive factors (among baseline characteristics) of the achievement\\n',\n",
       " 'of the main treatment goal;\\n',\n",
       " '- Evaluate the level of agreement between the dimensions reported by the patient and by\\n',\n",
       " 'the treating physician;\\n',\n",
       " '- Evaluate at 52 weeks the percentage of patients for whom the therapeutic objective\\n',\n",
       " 'initially achieved at the 1st follow-up visit is still maintained;\\n',\n",
       " '- Evaluate the percentage of patients who change their therapeutic objective after 12/16\\n',\n",
       " 'weeks of treatment;\\n',\n",
       " '- Follow the evolution of the PASI score (at 12/16 and 52 weeks);\\n',\n",
       " '- Level of accordance between PASI 90/100 and the satisfaction level in regard to the\\n',\n",
       " 'therapeutic objective set by the PSO-TARGET QoL Component grid;\\n',\n",
       " '- Follow the evolution of the DLQI score (at 12/16 and 52 weeks).\\n',\n",
       " 'Study design\\n',\n",
       " 'PSO-TARGET is an observational, non-interventional, prospective, multicentric,\\n',\n",
       " 'international, European study requiring no change in the patients’ standard of care (RIPH3 in\\n',\n",
       " 'France).\\n',\n",
       " 'Population\\n',\n",
       " 'Adult patients suffering from moderate to severe psoriasis vulgaris for whom the\\n',\n",
       " 'dermatologist decided to prescribe a treatment with Kyntheum®.\\n',\n",
       " 'Variables\\n',\n",
       " 'Primary endpoint\\n',\n",
       " '- At 12/16 weeks, level of concordance between the satisfaction level in regard to the\\n',\n",
       " 'therapeutic objective set by the PSO-TARGET QoL Component grid and the DLQI in\\n',\n",
       " 'assessing the impact of the treatment on the patients’ quality of life.\\n',\n",
       " 'Secondary endpoints\\n',\n",
       " '- At week 12/16, post Kyntheum® treatment, the percentage of patients who achieved the\\n',\n",
       " 'main treatment goal identified by the patient himself in the QoL component grid at\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 14 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'baseline. The therapeutic objective achievement is defined as “satisfied” or “very\\n',\n",
       " 'satisfied” response on 4 points Likert scale.\\n',\n",
       " '- Level of concordance between the satisfaction level in regard to the therapeutic\\n',\n",
       " 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up\\n',\n",
       " 'visit (52 ± 4 weeks.).\\n',\n",
       " '- Research of predictive factors (among baseline characteristics) of the achievement of the\\n',\n",
       " 'main treatment goal.\\n',\n",
       " '- Percentage of agreement between the physician-reported and the patient-reported\\n',\n",
       " 'dimensions at the first follow-up visit.\\n',\n",
       " '- Rate of patients having changed objective at the 1st follow-up visit (12/ 16 weeks).\\n',\n",
       " '- Percentage of patients who have maintained at 52 ± 4 weeks the level of satisfaction\\n',\n",
       " 'achieved at the 1st follow-up visit.\\n',\n",
       " '- PASI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit\\n',\n",
       " '(52 ± 4 weeks.).\\n',\n",
       " '- Level of accordance between PASI 90/100 and the satisfaction level in regard to the\\n',\n",
       " 'therapeutic objective set by the PSO-TARGET QoL Component grid.\\n',\n",
       " '- DLQI Scores at baseline, at the 1st follow-up visit (12/ 16 weeks), at the 2nd follow-up visit\\n',\n",
       " '52 ± 4 weeks.\\n',\n",
       " 'Data sources\\n',\n",
       " 'Patients’ data will be collected at day 0, at the 1st follow-up visit (12/16weeks) and at the\\n',\n",
       " '2nd follow-up visit at 52 ± 4 weeks according to the physician’s practice.\\n',\n",
       " 'As a prospective study, the following data will be collected during the patient visit:\\n',\n",
       " 'disease history, concomitant treatments, previous anti psoriatic treatment and adverse events.\\n',\n",
       " 'In addition, the following study specific data will be collected: disease severity (PASI score),\\n',\n",
       " 'quality of life questionnaires (DLQI, PSO-TARGET component grid).\\n',\n",
       " 'Study size\\n',\n",
       " 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who\\n',\n",
       " 'consider their target objective as being achieved after 12/16 weeks of treatment as defined\\n',\n",
       " 'by a “satisfied or very satisfied” response, assessed on a 4 points Likert scale, among patients\\n',\n",
       " 'with a DLQI total score of 0 or 1).\\n',\n",
       " 'The sample size calculation is based on the following hypotheses :\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 15 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '\\uf0fc Sensitivity : 90%\\n',\n",
       " '\\uf0fc Absolute precision : 10%\\n',\n",
       " '\\uf0fc Type I error : 5%\\n',\n",
       " '\\uf0fc Power at 80%\\n',\n",
       " '\\uf0fc Prevalence: 80% (estimated rate of patients with a DLQI 0-1 after 12 weeks of\\n',\n",
       " 'treatment.\\n',\n",
       " 'Based on these hypotheses, the sample size needed is estimated at 134 evaluable patients.\\n',\n",
       " 'Assuming 10% of patients will not be evaluable on main criterion, 150 patients have to be\\n',\n",
       " 'included.\\n',\n",
       " 'Data analysis\\n',\n",
       " 'Analysis of the primary endpoint\\n',\n",
       " 'The performance of the PSO-TARGET QoL component grid to assess the treatment impact on\\n',\n",
       " 'the patients’ quality of life will be determined by calculating the sensitivity and specificity of\\n',\n",
       " 'the grid compared to the DLQI (reference). The grid will be validated if both the specificity and\\n',\n",
       " 'sensitivity parameters reach the 85% threshold.\\n',\n",
       " 'Milestones\\n',\n",
       " 'Regulatory Submissions: Q2 2020\\n',\n",
       " 'Start of data collection Q3 2020\\n',\n",
       " 'End of data collection Q2 2022\\n',\n",
       " 'Final report Q4 2022\\n',\n",
       " '5 Amendments and Updates\\n',\n",
       " 'None\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 16 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '6 Milestones\\n',\n",
       " 'Planned dates for study milestones are indicated in the table below:\\n',\n",
       " 'Milestone Planned Date\\n',\n",
       " 'Start of data collection Q3 2020\\n',\n",
       " 'End of data collection Q2 2022\\n',\n",
       " 'Final study report Q4 2022\\n',\n",
       " 'The start of the study is defined as the date on which the first information on a study patient\\n',\n",
       " 'is recorded in the study dataset. LEO will ensure that End-of-Data Collection (End of Study)\\n',\n",
       " 'notification is submitted to the concerned authorities and IECs for each site, for each country\\n',\n",
       " 'and for the complete study.\\n',\n",
       " 'Based on upcoming knowledge, LEO might choose to terminate the study prematurely. In such\\n',\n",
       " 'case the Committee(s), study sites, IECs and authorities will be informed promptly.\\n',\n",
       " '7 Rationale and Background\\n',\n",
       " 'Psoriasis is a chronic, immune-mediated inflammatory skin disease. Clinical manifestations of\\n',\n",
       " 'psoriasis can be of multiple forms, including, among others, plaque psoriasis, guttate psoriasis,\\n',\n",
       " 'palmoplantar psoriasis, and pustular psoriasis (Lebwohl, 2018). Psoriasis is characterized by an\\n',\n",
       " 'abnormal keratinocyte proliferation in the interfollicular epidermis along with an infiltration\\n',\n",
       " 'of antigen-presenting cells and release of pro inflammatory cytokines, leading to a local\\n',\n",
       " 'inflammation (Ippagunta et al., 2016; Lowes et al., 2007). The aetiology of the disease is not\\n',\n",
       " 'fully understood, but a number of risk factors are recognized, including family history and\\n',\n",
       " 'environmental risk factors, such as smoking, stress, obesity, and alcohol consumption (Huerta\\n',\n",
       " 'et al., 2007). The prevalence of psoriasis is difficult to evaluate with precision but is estimated\\n',\n",
       " 'around 2-4% in western countries (Gelfand et al., 2005; Kurd and Gelfand, 2009; Stern et al.,\\n',\n",
       " '2004). In France, the prevalence of psoriasis is estimated to 4,4 % (Richard et al., 2018).\\n',\n",
       " 'Psoriasis causes considerable psychosocial disability and has a major impact on patients’\\n',\n",
       " 'quality of life (Krueger et al., 2001).\\n',\n",
       " 'The severity of psoriasis can be influenced by a great variety of factors including extent of the\\n',\n",
       " 'disease, inflammation, lesions location and impact on quality of life. As those factors can\\n',\n",
       " 'fluctuate over time, so can the intensity of the disease and more importantly the patient’s\\n',\n",
       " 'perception of his/her affliction. The current standard of care for treatment of psoriasis\\n',\n",
       " 'primarily focusing on the reduction of the skin symptoms as defined by the Psoriasis Area\\n',\n",
       " 'Severity Index (PASI), somewhat setting asides the patient’s feelings in terms of which aspects\\n',\n",
       " 'of his/her life are affected by the disease. Indeed, a multinational study has already shown\\n',\n",
       " 'that a discrepancy exists between the physician’s assessment of the disease severity and the\\n',\n",
       " 'patient’s (van de Kerkhof et al., 2015). This could be, at least partially, explained by the use of\\n',\n",
       " 'standardized tools, by the physician which not necessarily take into consideration the patients\\n',\n",
       " 'therapeutic expectation which could sometimes be a subjective parameter. (van de Kerkhof\\n',\n",
       " 'et al., 2015). Currently, the higher efficacy observed with new biologics means that PASI 90 or\\n',\n",
       " 'even PASI 100 response are increasingly being considered as a new treatment goal (Daudén et\\n',\n",
       " 'al., 2016; Kerdel and Zaiac, 2015; Lebwohl et al., 2015). However, other quality of life aspects\\n',\n",
       " 'of chronic affections such as psoriasis that are not being assessed by tools like the PASI, must\\n',\n",
       " 'not be overlooked Multiple patient reported outcomes (PRO) questionnaires are available to\\n',\n",
       " 'evaluate the impact of the disease on patients’ quality of life. Among the available PROs, the\\n',\n",
       " 'Dermatology Life Quality Index (DLQI) is the most frequently used (Puig et al., 2017). It is\\n',\n",
       " 'composed of ten questions grouped in 6 domains “symptoms and feelings”, “daily activities”,\\n',\n",
       " '“leisure”, “work/school”, “personal relationships” and “treatment”. Each answer is graded\\n',\n",
       " 'from 0 to 3. The DLQI is calculated by adding the score of each question, resulting in a\\n',\n",
       " 'maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.\\n',\n",
       " \"A score higher than 10 indicates that the patient's life is being severely affected by their skin\\n\",\n",
       " 'disease (Finlay and Khan, 1994). However, the DLQI is a standardized tool which missing\\n',\n",
       " 'potentially some quality of life specific issues for psoriasis patient. Consequently, among\\n',\n",
       " 'patients, some cannot seem to completely restore a normal quality of life (DLQI 0-1) even\\n',\n",
       " 'though they reached a perfect PASI score (100). This phenomenon may be explained by the\\n',\n",
       " 'fact that the patient’s own perception can be different from the physician’s perspective and\\n',\n",
       " 'may have changed between follow-ups. Although, the Patient Benefit Index has been devised\\n',\n",
       " 'to allow the patient to weigh the therapeutic goals in order to define which ones are the most\\n',\n",
       " 'important for him/her (using a 4 points Likert Scale, (Augustin et al., 2008)), it is not\\n',\n",
       " 'discriminatory enough towards the patient’s principal expectation (Feuerhahn et al., 2012).\\n',\n",
       " 'In addition, it is widely recognized that alexithymia (difficulty to express emotion) is more\\n',\n",
       " 'prevalent in the psoriasis patients than in the general population and psoriasis patients with\\n',\n",
       " 'alexithymia appear to suffer higher psoriasis burden as they have more difficulties to express\\n',\n",
       " 'their expectations (Sampogna et al., 2017). Since these patients struggle to recognize and\\n',\n",
       " 'verbalize their emotions, it can be useful and informative to offer patients a variety of verbatim\\n',\n",
       " 'in which they can identify. Taken together these elements plea for a novel approach that take\\n',\n",
       " 'more into consideration the patient’s expectations prior to treatment initiation and not only\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 18 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'the dermatologist symptomatic approach. We therefore believe that it is of importance to\\n',\n",
       " 'assess the 4 components of quality of life usually impacted in case of chronic disease as\\n',\n",
       " 'defined by Chassany (Chassany, 2003; Forestier et al., 2019), before initiating the systemic\\n',\n",
       " 'treatment, in order to define better therapeutics goals in an holistic approach. It is necessary\\n',\n",
       " 'to assess this new approach in a homogenous population, thus only patients starting a biologic\\n',\n",
       " 'treatment by Kyntheum® at the inclusion in the study will be enrolled. Indeed, satisfaction\\n',\n",
       " 'towards a treatment may be influenced by several factors including administration regimen.\\n',\n",
       " 'The aim of this study is to evaluate, compared to the DLQI as a standard tool, the\\n',\n",
       " 'sensitivity and specificity of the PSO-TARGET QoL Component grid as a new QoL questionnaire\\n',\n",
       " 'for assessing the level of satisfaction of the psoriasis patients in achieving the therapeutic goal,\\n',\n",
       " 'identified by himself, after a biologic treatment. This study is the first step of an evaluation\\n',\n",
       " 'process aiming to validate the PSO-TARGET QoL Component grid. Ultimately, this tool will be\\n',\n",
       " 'used by physicians to devise a “Treat to patient satisfaction target” strategy that better suits\\n',\n",
       " 'their patients’ expectations. To construct this new questionnaire, the first step has been to\\n',\n",
       " 'collect psoriasis patients’ feedback on what is the aspect of their life that is the most impacted\\n',\n",
       " 'by the disease and which is the one they would want to improve the most. To this aim a\\n',\n",
       " 'retrospective survey based on the recollection and experience from 3 clinical dermatologists\\n',\n",
       " '(2 French and 1 Belgian) of patient’s expectations, was conducted. The results of the survey\\n',\n",
       " 'have been used to generate a table containing 12 treatment goals equally distributed into the\\n',\n",
       " '4 major components classically used in quality of life studies in patients suffering from chronic\\n',\n",
       " 'diseases (physical, subjective, relational/social and therapeutic) (Chassany, 2003; Forestier et\\n',\n",
       " 'al., 2019). The proposed verbatim was then reviewed by a psychologist to ensure that there\\n',\n",
       " 'was a balance between the proposals; i.e. the vocabulary used was neutral enough not to\\n',\n",
       " 'guide the choices. This component grid will be administered to the patients prior to the\\n',\n",
       " 'initiation of a systemic treatment (Kyntheum® / brodalumab) to set up the main therapeutic\\n',\n",
       " 'objective (1 out of 12) fitting with his priority expectation from the upcoming treatment. The\\n',\n",
       " 'patient will only have access to the 12 treatment goals but not to the category headings.\\n',\n",
       " 'Because of the fact that alexithymia is highly prevalent in psoriasis patients, the grid will be\\n',\n",
       " 'submitted to the patient after he/she had been asked by the physician to express\\n',\n",
       " 'spontaneously his/her treatment expectations. This should help the patient to narrow down\\n',\n",
       " 'the item where his/her expectation belongs. At the 1st follow-up visit (12/16 weeks), the level\\n',\n",
       " 'of achievement will be assessed using a 4 points Likert scale (“very satisfied”, “satisfied”,\\n',\n",
       " '“unsatisfied”, “very unsatisfied”). In order to evaluate the sensitivity and the specificity of the\\n',\n",
       " 'PSO-TARGET QoL component grid, the primary objective of the study will be to estimate the\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 19 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'level of concordance of this satisfaction level and the overall quality of life as defined by the\\n',\n",
       " 'DLQI at the same time point. It is important to consider that systemic treatment by Kyntheum®\\n',\n",
       " 'is an accessory to the study but the objective of the PSO-TARGET is not to evaluate Kyntheum®\\n',\n",
       " 'efficacy.\\n',\n",
       " 'As part of secondary objectives, in parallel to that initial assessment by the patient, the\\n',\n",
       " 'physician will tick on the grid what would be his patients therapeutic goal based on what he\\n',\n",
       " 'knows/understands from the patient’s disease history and therapeutic desires. At the time of\\n',\n",
       " 'his/her assessment, the physician will be blinded of the patient’s choice of therapeutic goal.\\n',\n",
       " 'The accordance between the physician-chosen and the patient-chosen dimensions will be\\n',\n",
       " 'analyzed. The 12 items of the tool will be pooled and analysed by component (physical,\\n',\n",
       " 'subjective, relational and therapeutic). At 52 weeks, among other secondary endpoints, the\\n',\n",
       " 'maintenance of the level of achievement of the initial objective observed at the 1st follow-up\\n',\n",
       " 'visit, will be assessed.\\n',\n",
       " 'One of the innovative aspects of this exploratory observational study will be the\\n',\n",
       " 'administration of a psoriasis-specific quality of life component grid containing 12 treatment\\n',\n",
       " 'objectives grouped in the 4 quality of life components/dimensions usually impacted in patients\\n',\n",
       " 'suffering from chronic diseases (Chassany, 2003; Forestier et al., 2019). Those dimensions\\n',\n",
       " 'accounting for the burden to bear when suffering from a chronic disease are the following:\\n',\n",
       " 'Physical, Subjective, Relational/Social and Therapeutic. Each dimension will include 3 patient’s\\n',\n",
       " 'therapeutic goal based on dermatologists’ clinical experience and reviewed by an expert on\\n',\n",
       " 'psychometric tools.\\n',\n",
       " 'This is an exploratory study, a first step to assess the interest of the PSO-TARGET component\\n',\n",
       " 'grid. If the sensitivity and specificity reach an acceptable threshold (85%), the potential of the\\n',\n",
       " 'PSO-TARGET grid will be considered for validation in larger clinical studies. Indeed, more\\n',\n",
       " 'studies will be needed to test other attributes in order to fully validate the PSO-TARGET grid\\n',\n",
       " 'as an alternative to the DLQI for QoL assessment. Once the PSO-TARGET component grid is\\n',\n",
       " 'validated, it will prove to be a useful tool for a better design of a therapeutic objective from\\n',\n",
       " 'the physician and thus a better care brought to the patient which should improve the patient’s\\n',\n",
       " 'satisfaction and treatment adherence.\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 20 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '8 Research Question and Objectives\\n',\n",
       " 'Primary Objective\\n',\n",
       " 'The primary endpoint will be the evaluation at week 12/16 of the sensitivity and the specificity,\\n',\n",
       " 'compared to the DLQI as a standard, of the PSO-TARGET QoL component grid to assess the\\n',\n",
       " 'level of satisfaction of patient achieving the therapeutic goal, identified by himself.\\n',\n",
       " 'The therapeutic objective will be considered as achieved if the patient gives the responses\\n',\n",
       " '“Satisfied” or “Very Satisfied” on the Likert scale. The response will then be compared to the\\n',\n",
       " 'DLQI score at 12/16 weeks.\\n',\n",
       " 'Secondary Objectives\\n',\n",
       " '- Evaluate the percentage of patients who consider their target objective as being achieved\\n',\n",
       " 'after 12/16 weeks of treatment as defined by a “satisfied or very satisfied” response.\\n',\n",
       " '- Level of concordance between the satisfaction level in regard to the therapeutic\\n',\n",
       " 'objective set by the PSO-TARGET QoL Component grid and the DLQI at the 2nd follow-up\\n',\n",
       " 'visit (52 ± 4 weeks.).\\n',\n",
       " '- Evaluate the level of agreement between the dimensions reported by the patient and by\\n',\n",
       " 'the treating physician at baseline.\\n',\n",
       " '- Follow the degree of completeness of the main treatment goal identified at baseline after\\n',\n",
       " '52 weeks.\\n',\n",
       " '- Follow evolution of the PASI score (at 12/16 and 52 weeks).\\n',\n",
       " '- Level of accordance between PASI 90/100 and the satisfaction level in regard to the\\n',\n",
       " 'therapeutic objective set by the PSO-TARGET QoL Component grid.\\n',\n",
       " '- Follow evolution of the DLQI score (at 12/16 and 52 weeks).\\n',\n",
       " '- Evaluate the rate of patients who change their therapeutic objective after 12/16 weeks\\n',\n",
       " 'of treatment.\\n',\n",
       " '9 Research Method\\n',\n",
       " 'Study Design\\n',\n",
       " 'Eligibility criteria\\n',\n",
       " 'The inclusion criteria are the following:\\n',\n",
       " '\\uf0b7 Age > 18 years\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 21 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '\\uf0b7 Patient for whom the dermatologist decided to initiate a treatment by Kyntheum®\\n',\n",
       " 'according to SmPC.\\n',\n",
       " '\\uf0b7 Patient who signed an informed consent.\\n',\n",
       " 'The following non-inclusion criteria will be applied:\\n',\n",
       " '\\uf0b7 Vulnerable subjects according to the law;\\n',\n",
       " 'o pregnant, parturient or breast feeding women;\\n',\n",
       " 'o deprived of their freedom by administrative, medical or legal decision or\\n',\n",
       " 'who is under trusteeship/guardianship;\\n',\n",
       " 'o legally protected, or unable to express their consent to participate;\\n',\n",
       " 'o With no affiliation to a social security system;\\n',\n",
       " '\\uf0b7 Psychologically/linguistically unable to express their consent to participate;\\n',\n",
       " '\\uf0b7 With an hypersensitivity to at least one of the excipients of Kyntheum®;\\n',\n",
       " '\\uf0b7 Participating at the same time in another clinical trial.\\n',\n",
       " 'PSO-TARGET Quality of Life Component grid.\\n',\n",
       " 'As a first step to construct the component grid, a retrospective survey based on the\\n',\n",
       " 'recollection and experience from 3 clinical dermatologists (2 French and 1 Belgian) of patient’s\\n',\n",
       " 'expectations, has been conducted. The results of the survey have been used to generate a grid\\n',\n",
       " 'containing 12 therapeutic goals equally distributed into the 4 major psychometric components\\n',\n",
       " 'classically used in quality of life studies in patients suffering from chronic diseases (Chassany,\\n',\n",
       " '2003; Forestier et al., 2019). These four dimensions (cf table 1) are the following:\\n',\n",
       " '- Physical: autonomy, physical capabilities, ability to perform daily activities;\\n',\n",
       " '- Subjective: linked to experienced emotion, anxiety, well-being;\\n',\n",
       " '- Relational/social: with family, friendship or professional environment, engaging\\n',\n",
       " 'personal relationships, involvement in social or leisure activities;\\n',\n",
       " '- Therapeutic: linked to treatment, for ex. treatment-/care-related discomfort.\\n',\n",
       " 'The investigators participating to the study will agree to implement this table as part of their\\n',\n",
       " 'standard of care along with the DLQI questionnaire.\\n',\n",
       " 'Table 1: Quality of Life (QoL) component grid\\n',\n",
       " 'Physical Subjective Relational/ social Therapeutic\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Stu\\n',\n",
       " '\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 22 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Not be\\n',\n",
       " 'limited/handicaped by\\n',\n",
       " 'the pain\\n',\n",
       " 'Think less or not at all about\\n',\n",
       " 'the disease\\n',\n",
       " 'Spend quality time with family,\\n',\n",
       " 'friends or colleagues\\n',\n",
       " 'Need to think less about\\n',\n",
       " 'treatment and care\\n',\n",
       " 'Do not feel any\\n',\n",
       " 'functional discomfort\\n',\n",
       " '(itching, rash) in my\\n',\n",
       " 'daily activities\\n',\n",
       " 'Do not feel any anxiety from\\n',\n",
       " 'the disease\\n',\n",
       " 'Not caring about what people think\\n',\n",
       " 'about me\\n',\n",
       " 'Encounter very few, if any,\\n',\n",
       " 'drug discomfort\\n',\n",
       " 'Have freedom of\\n',\n",
       " 'movement and\\n',\n",
       " 'activities\\n',\n",
       " 'Feel serene, have peace of\\n',\n",
       " 'mind Have a fulfilling intimate life To be cured quickly\\n',\n",
       " 'This grid will be administered to the enrolled patients after signature of the informed consent.\\n',\n",
       " 'The patient will be requested to identify what would be his/her main treatment objective.\\n',\n",
       " 'Only one item from the list will be picked by the patient. The investigator must not influence\\n',\n",
       " 'the patient into choosing a specific component to the table. The patient will have a grid with\\n',\n",
       " '12 proposals in front of him/her and will not be aware of the dimensions to which the\\n',\n",
       " 'proposals relate. The four dimensions typically described in chronic diseases will be considered\\n',\n",
       " 'only for analysis, but not submitted to patients. The patient will be given some space and time\\n',\n",
       " 'to choose the component without any help or supervision from the investigator. This is\\n',\n",
       " 'requested in order to avoid social desirability, defined as the tendency of some respondents\\n',\n",
       " 'to report an answer in a way they deem to be more socially acceptable than would be their\\n',\n",
       " '\"true\" answer. The patient will then conceal his/her response in a provided envelope without\\n',\n",
       " 'revealing the chosen component to the physician.\\n',\n",
       " 'In the meantime, the treating physician will identify the therapeutic objective that is\\n',\n",
       " 'supposedly the most important for his patient, based on his/her discussion with him. The\\n',\n",
       " 'physician-reported component will be concealed in a separate envelope and compared with\\n',\n",
       " 'the patient-chosen component during the analysis of the secondary endpoints.\\n',\n",
       " 'As the primary endpoint of the study, the level of achievement of this therapeutic goal at 3\\n',\n",
       " 'months (12/16 weeks) will be assessed by a 4-points Likert scale (Very Unsatisfied; Unsatisfied;\\n',\n",
       " 'Satisfied; Very Satisfied), and compared to the DLQI scoring classes.\\n',\n",
       " 'Dermatology Quality of Life Index (DLQI)\\n',\n",
       " 'The DLQI is designed to measure the health-related quality of life of adult patients suffering\\n',\n",
       " 'from a skin disease. It can be administered in patients aged 16 years and over and takes only\\n',\n",
       " \"few minutes to complete. The DLQI consists of 10 questions concerning patients' perception\\n\",\n",
       " 'of the impact of skin diseases on different aspects of their health-related quality of life over\\n',\n",
       " 'the last week. It is not specific to psoriasis and is the most frequently used patient reported\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 23 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'outcome measure in randomised controlled trials in dermatology in general and in psoriasis\\n',\n",
       " 'more specifically (Cardiff University, 2019; Puig et al., 2017).\\n',\n",
       " 'The DLQI is composed of ten questions grouped in 6 domains “symptoms and feelings”, “daily\\n',\n",
       " 'activities”, “leisure”, “work/school”, “personal relationships” and “treatment”. To each\\n',\n",
       " 'question the patient will have the followings choices: “Very much”, “A lot”, “A little”, “Not at\\n',\n",
       " 'all” or “not relevant”\\n',\n",
       " 'Each answer is graded from 0 (“not relevant”, “not at all” or not answered) to 3 (“very much”).\\n',\n",
       " 'The DLQI is calculated by adding the score of each question, resulting in a maximum of 30 and\\n',\n",
       " 'a minimum of 0. The higher the score, the more quality of life is impaired. A score higher than\\n',\n",
       " \"10 indicates that the patient's life is being severely affected by their skin disease (Finlay and\\n\",\n",
       " 'Khan, 1994).\\n',\n",
       " 'More specifically, the total score will be divided into the following subcategories:\\n',\n",
       " '\\uf0b7 0-1 = no effect at all on patient’s life;\\n',\n",
       " '\\uf0b7 2-5 = small effect on patient’s life;\\n',\n",
       " '\\uf0b7 6-10 = moderate effect on patient’s life;\\n',\n",
       " '\\uf0b7 11-20 = very large effect on patient’s life;\\n',\n",
       " '\\uf0b7 21-30 = extremely large effect on patient’s life.\\n',\n",
       " 'Limitation of bias\\n',\n",
       " 'In order to limit bias, the sensitivity and specificity analysis need to be performed on a\\n',\n",
       " 'population as homogenous as possible. To this end, only patients treated with brodalumab\\n',\n",
       " '(Kyntheum®) will be enrolled. By doing so we will limit the bias due to different treatment\\n',\n",
       " 'profiles (schedule of drug administration....). However, Kyntheum® efficacy will not be\\n',\n",
       " 'assessed during the study.\\n',\n",
       " 'Study Schedule\\n',\n",
       " 'The enrolment period is expected to be 5 months. After the patient’s individual\\n',\n",
       " 'treatment plan has been decided, he/she will be approached for informed consent to\\n',\n",
       " 'participate in the study and deliver data to use for national and pooled analysis.\\n',\n",
       " 'Investigators are expected to enter data into the site specific part of the CRF at baseline and\\n',\n",
       " 'at any patient contact throughout the duration of the study. In order to complete and sign-off\\n',\n",
       " 'the CRF, a medical record may be used as source for historical data.\\n',\n",
       " 'Visits will be according to local clinical practice and not decided in advance by the study\\n',\n",
       " 'protocol.\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 24 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Relevant data from every visit within 52 weeks after baseline will be collected.\\n',\n",
       " 'For analysis the following applies:\\n',\n",
       " 'Visits that falls within week 12/-16 weeks are proxy for visit at 3 months. If more than one visit\\n',\n",
       " 'within this period, the visit closest to week 16 will be used for analysis.\\n',\n",
       " 'Visits that falls within week 48-56 weeks are proxy for visit at 12 months (52 weeks ± 4) .If\\n',\n",
       " 'more than one visit within this period, the visit closest to week 52 will be used for analysis.\\n',\n",
       " 'The study design is the following:\\n',\n",
       " 'The study will enrol consecutive patients planned to receive Kyntheum® and fulfilling the\\n',\n",
       " 'eligibility criteria. The assignment of the patient to Kyntheum® must not be decided in advance\\n',\n",
       " 'by the trial protocol, but must fall within current practice, and the prescription shall be clearly\\n',\n",
       " 'separated from the decision to include the patient in the study. The visit schedule is defined\\n',\n",
       " 'by the standard of care as there is no extra mandatory visits related to the participation in the\\n',\n",
       " 'study. Patients must be informed about the study and asked for consent to use their data, and\\n',\n",
       " 'patients willing to participate be enrolled.\\n',\n",
       " 'Definition of a non-interventional study\\n',\n",
       " 'The study is a ‘non-interventional study’ as defined for drug studies in Directive 2001/20/EC\\n',\n",
       " '(European Commission, 2001) with primary data collection and will follow the guidelines for\\n',\n",
       " 'Good Pharmacoepidemiology Practices (Public Policy Committee, 2016).\\n',\n",
       " 'This means that:\\n',\n",
       " '\\uf0b7 The medicinal product is prescribed in the usual manner in accordance with the terms\\n',\n",
       " 'of the marketing authorisation;\\n',\n",
       " '\\uf0b7 The assignment of the patient to a particular therapeutic strategy is not decided in\\n',\n",
       " 'advance by a trial protocol but falls within current practice and the prescription of the\\n',\n",
       " 'medicine is clearly separated from the decision to include the patient in the study\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 25 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '\\uf0b7 No additional diagnostic or monitoring procedures are applied to the patients.\\n',\n",
       " 'Interviews, questionnaires, blood samples and patient follow-up may be performed as\\n',\n",
       " 'part of normal clinical practice.\\n',\n",
       " '\\uf0b7 Epidemiological methods are used for the analysis of collected data.\\n',\n",
       " 'Setting\\n',\n",
       " 'The study is planned to be conducted in approximatively 25 sites in 2 countries. Investigators\\n',\n",
       " 'will be clinical dermatologists. Each participating site is expected to include in average 5/6\\n',\n",
       " 'patients. In case of slow recruitment in some sites, the other sites will be allowed to enrol up\\n',\n",
       " 'to 10 patients. Inclusion requires that Kyntheum® is prescribed in accordance with the\\n',\n",
       " 'approved terms of the marketing authorization in the country and that none of the stated\\n',\n",
       " 'contraindications apply.\\n',\n",
       " 'Caution should be taken by the treating physician concerning any precautions, warnings and\\n',\n",
       " 'potential drug interactions stated in the product label.\\n',\n",
       " 'Patients should be included in the study only once.\\n',\n",
       " 'The study aims to involve sites and investigators that are representative for HCPs that prescribe\\n',\n",
       " 'biologics to patients suffering from psoriasis vulgaris. Sites can be hospital (university, private,\\n',\n",
       " 'public) dermatology departments, private dermatology clinics, and all sorts of general\\n',\n",
       " 'practices. Sites where patients are prescribed Kyntheum®, but for continuation of care are\\n',\n",
       " 'routinely referred to a different site without access to prescribe Kyntheum®, should not be\\n',\n",
       " 'selected for this study.\\n',\n",
       " 'Information about the PSO-TARGET study should be given after the decision is made to\\n',\n",
       " 'treat the patient with Kyntheum®. It will be emphasized that the participation study will not\\n',\n",
       " 'condition the patient treatment and will not alter the visit schedule defined by the standard\\n',\n",
       " 'of care (3 and 12 months). After enrolment (i.e. signature of the Informed Consent Form), the\\n',\n",
       " 'physician will provide the patient with the QoL component grid along with the DLQI\\n',\n",
       " 'questionnaire. After having explained the purpose of the table in regards to the study, the\\n',\n",
       " 'physician shall give the patient enough time to reflect on which component is the most\\n',\n",
       " 'important for him/her without influencing him/her. Both questionnaires will be answered\\n',\n",
       " 'after this reflection period.\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 26 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Variables\\n',\n",
       " 'The following data will be collected from the patients’ medical records and reported on the\\n',\n",
       " 'CRF by the investigator.\\n',\n",
       " 'Consent\\n',\n",
       " '\\uf0b7 Unique Study subject number (ISO three letter Country Code, followed by site number\\n',\n",
       " 'within country and consecutive patient number within site)\\n',\n",
       " '\\uf0b7 Date of Informed Consent (dd.MMM.yyyy)\\n',\n",
       " '\\uf0b7 Date of first case report recording (dd.MMM.yyyy)\\n',\n",
       " 'Demographics\\n',\n",
       " '\\uf0b7 Month/Year of Birth (MMM.yyyy)\\n',\n",
       " '\\uf0b7 Gender (Male/Female)\\n',\n",
       " '\\uf0b7 Weight (kg)\\n',\n",
       " '\\uf0b7 Height (cm)\\n',\n",
       " 'Medical History\\n',\n",
       " '\\uf0b7 Date of diagnosis of psoriasis (dd.MMM.yyyy)\\n',\n",
       " '\\uf0b7 Location of Psoriasis (List: scalp, nail, body, joint involvement, genital or intimate\\n',\n",
       " 'psoriasis, other)\\n',\n",
       " '\\uf0b7 Body Surface Area (xx%)\\n',\n",
       " '\\uf0b7 Commonly associated comorbidities (List: cardiovascular diseases, diabetes,\\n',\n",
       " 'hypertension, depression, psoriasis arthritis, inflammatory bowel disease, other)\\n',\n",
       " '\\uf0b7 Smoking habits (never, active with pack years, not active with pack years and years\\n',\n",
       " 'since stopped)\\n',\n",
       " '\\uf0b7 Alcohol consumption (never, occasionally or regularly with number of days/week,\\n',\n",
       " 'number of drinks per day when alcohol is used)\\n',\n",
       " '\\uf0b7 Prior psoriasis treatment and posology + reason for discontinuation of the last therapy\\n',\n",
       " 'administered\\n',\n",
       " '\\uf0b7 Standard occupational category.\\n',\n",
       " 'Psoriasis treatments during study period\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 27 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " '\\uf0b7 Study treatment & co-medications (product name, formulation, dose, number of\\n',\n",
       " 'prescribed packages, package size)\\n',\n",
       " '\\uf0b7 Date of treatment initiation\\n',\n",
       " '\\uf0b7 Date of discontinuation (dd.MMM.yyyy)\\n',\n",
       " '\\uf0b7 Reason for discontinuation (noncompliance, adverse event, requirement for\\n',\n",
       " 'alternative therapy, death, pregnancy, other)\\n',\n",
       " 'Severity/effectiveness\\n',\n",
       " '\\uf0b7 Psoriasis area and severity index (PASI)\\n',\n",
       " 'Patient Reported Outcome\\n',\n",
       " '\\uf0b7 Dermatology Life Quality Index (DLQI) score\\n',\n",
       " '\\uf0b7 PSO-TARGET QoL component grid\\n',\n",
       " 'The collected data are presented in the following flow chart of the \\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 28 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'Data Source\\n',\n",
       " 'Investigator will complete the CRF with assessments and information according to the\\n',\n",
       " 'protocol. In addition, participants (patients) will be asked to enter data about their psoriasis\\n',\n",
       " 'symptoms and their Quality of Life, during the data collection period.\\n',\n",
       " 'The below described scores will be mandatory:\\n',\n",
       " 'Psoriasis Area and Severity Index (PASI) is the most widely used tool for the measurement of\\n',\n",
       " 'severity of psoriasis in clinical research. PASI combines the assessment of the severity\\n',\n",
       " 'of lesions and the area affected into a single absolute score in the range 0 (no disease) to 72\\n',\n",
       " '(maximal disease).\\n',\n",
       " 'Reporter\\n',\n",
       " 'Data to be collected Base-line\\n',\n",
       " 'Visit (Day 0)\\n',\n",
       " '3 months Visit\\n',\n",
       " '(week 12-16)\\n',\n",
       " '12 months visit\\n',\n",
       " '(week 48-56)\\n',\n",
       " 'Investigator\\n',\n",
       " 'Unique Study subject\\n',\n",
       " 'Month/Year of Birth\\n',\n",
       " 'Gender\\n',\n",
       " 'Weight\\n',\n",
       " 'Height\\n',\n",
       " 'Date of diagnosis\\n',\n",
       " 'Location of Psoriasis\\n',\n",
       " 'Body Surface Area\\n',\n",
       " 'Commonly associated comorbidities\\n',\n",
       " 'Smoking habits\\n',\n",
       " 'Alcohol consumption\\n',\n",
       " 'Prior psoriasis treatment\\n',\n",
       " 'Psoriasis treatment during study period\\n',\n",
       " 'Date of discontinuation of psoriasis treatment during study\\n',\n",
       " 'period\\n',\n",
       " 'Reason for discontinuation of psoriasis treatment during study\\n',\n",
       " 'period\\n',\n",
       " 'PASI\\n',\n",
       " 'QoL component grid\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'Patient DLQI\\n',\n",
       " 'PSO-TARGET QoL component grid\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'X\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 29 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'The Dermatology Quality of Life Index (DLQI) is well recognized Quality of Life questionnaire\\n',\n",
       " 'in psoriasis and capture a combination of symptoms, impact on daily routines, and feeling of\\n',\n",
       " 'stigmatization. It is a simple 10-question validated questionnaire that has been used in over\\n',\n",
       " '40 different skin conditions in over 80 countries and is available in over 90 languages. Its use\\n',\n",
       " 'has been described in over 1000 publications including many multinational studies. It is\\n',\n",
       " 'recommended to provide indirect measure of disease severity and is well used in studies on\\n',\n",
       " 'psoriasis and mentioned in the UK-treatment guideline (for details, see section 9.1.3).\\n',\n",
       " 'The PSO-TARGET QoL component grid is a novel tool designed using a retrospective survey\\n',\n",
       " 'based on the recollection and experience from 3 clinical dermatologists of patient’s\\n',\n",
       " 'expectations. It contains 12 therapeutic goals equally distributed into the 4 major\\n',\n",
       " 'psychometric components classically used in quality of life studies in patients suffering from\\n',\n",
       " 'chronic diseases (Chassany, 2003; Forestier et al., 2019). These four dimensions are: physical,\\n',\n",
       " 'subjective, relational/social and therapeutic. It has never been used before since it was\\n',\n",
       " 'designed for the PSO-TARGET study. Each patient will be required to pick only one item in the\\n',\n",
       " 'grid as his/her main therapeutic goal (see section 9.1.2). Treatment satisfaction in regards to\\n',\n",
       " 'the chosen component will be assessed at 12/16 weeks and 52 weeks by a 4 points Likert Scale\\n',\n",
       " 'and the level of concordance will be compared to DLQI scoring classes (described in section\\n',\n",
       " '9.1.2).\\n',\n",
       " 'Study Size\\n',\n",
       " 'The main criterion is the sensitivity of the PSO-TARGET tool (percentage of patients who\\n',\n",
       " 'consider their target objective as being achieved after 12/16 weeks of treatment as defined\\n',\n",
       " 'by a “satisfied or very satisfied” response, assessed on a 4 points Likert scale, among patients\\n',\n",
       " 'with a DLQI total score of 0 or 1).\\n',\n",
       " 'The sample size calculation is based on the following hypotheses:\\n',\n",
       " 'Sensitivity: 90%\\n',\n",
       " 'Absolute precision : 10%\\n',\n",
       " 'Type I error : 5%\\n',\n",
       " 'Power at 80%\\n',\n",
       " 'Prevalence: 80% (estimated rate of patient with a DLQI 0-1 after 12 weeks of treatment)\\n',\n",
       " 'Hypothesis :\\n',\n",
       " 'NIS-PSO-TARGET Non-Interventional Study Protocol\\n',\n",
       " 'Study ID RCB: 2020-A00652-37\\n',\n",
       " 'Page 30 of 51\\n',\n",
       " 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\\n',\n",
       " 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\\n',\n",
       " 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\\n',\n",
       " 'H0 : Se = Se0\\n',\n",
       " 'H1 : Se = Se1 > Se0\\n',\n",
       " 'With Se=sensitivity, Se0=0.8 and Se1=0.9\\n',\n",
       " 'Using the binomial probability formula, the sample size necessary to meet both a significance\\n',\n",
       " 'level and a power requirement may be found by solving the following two equations\\n',\n",
       " 'simultaneously :\\n',\n",
       " 'Significance level B ( s1 > s α | n1, Se0) = α\\n',\n",
       " 'B (s1 > s α | n1, Se1) = 1 - β\\n',\n",
       " 'Where n1 : patients with a DLQI 0-1, s1 : patients with a DLQI 0-1 and a positive test outcome\\n',\n",
       " 'With α=0.05 and 1 - β=0.8\\n',\n",
       " 'To obtain n, n1 is inflated by the prevalence P (rate of patients with a DLQI 0-1 = 80%), to\\n',\n",
       " ...]"
      ]
     },
     "execution_count": 32,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 48,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3007\n",
      "3003\n",
      "3018\n",
      "3001\n",
      "3007\n",
      "3012\n",
      "3006\n",
      "3013\n",
      "3016\n",
      "1282\n"
     ]
    }
   ],
   "source": [
    "chunks = []\n",
    "total = 0\n",
    "\n",
    "i = 0\n",
    "while i < len(text):\n",
    "    chunk_tokens = 0\n",
    "    chunk = ''\n",
    "    while chunk_tokens <= 3000 and i < len(text):\n",
    "        chunk += text[i]\n",
    "\n",
    "        chunk_tokens = len(tokenizer(chunk)[0])\n",
    "        # print(chunk_tokens)\n",
    "        total += len(tokenizer(chunk)[0])\n",
    "        i += 1\n",
    "    print(len(tokenizer(chunk)[0]))\n",
    "    # print(chunk)\n",
    "    chunks.append(chunk)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "for chunk in chunks:\n",
    "    print(chunks)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "answers = []"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 51,
   "metadata": {},
   "outputs": [],
   "source": [
    "for chunk in chunks:\n",
    "    completion = openai.Completion.create(\n",
    "    model=\"text-davinci-003\",\n",
    "    prompt=f\"extract the validated clinical questionnaires used in this text:{chunk}\",\n",
    "    max_tokens=300,\n",
    "    temperature=0\n",
    "    )\n",
    "    answer = completion[\"choices\"][0][\"text\"]\n",
    "    answers.append(answer)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 55,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Page 10 of 51\n",
      "THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL, DELI-\n",
      "VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY\n",
      "WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S\n",
      "4 Abstract\n",
      "This Non-Interventional Study (NIS) is designed to evaluate the sensitivity and specificity of a\n",
      "novel Quality of Life (QoL) tool to assess the treatment satisfaction in psoriasis patients\n",
      "treated with brodalumab (Kyntheum®).\n",
      "The study will be conducted in France and will include a total of 300 patients with moderate to\n",
      "severe psoriasis. Patients will be recruited from dermatology clinics and hospitals.\n",
      "The primary objective of this study is to evaluate the sensitivity and specificity of the novel\n",
      "QoL questionnaire (treat to the PSOriasis patient satiSfactiOn TARGET) compared to the\n",
      "Dermatology Quality of Life Index (DLQI) as a standard tool.\n",
      "The secondary objectives are to evaluate the efficacy of brodalumab (Kyntheum®) in terms of\n",
      "Psoriasis Area and Severity Index (PASI) score, and to assess the safety\n",
      "\n",
      "objective set by the PSO-TARGET QoL Component grid and the PASI 90/100 in\n",
      "assessing the impact of the treatment on the patients’ quality of life.\n",
      "- Identification of predictive factors (among baseline characteristics) of the achievement\n",
      "of the main treatment goal;\n",
      "- Level of agreement between the dimensions reported by the patient and by the treating\n",
      "physician;\n",
      "- At 52 weeks, the percentage of patients for whom the therapeutic objective initially\n",
      "achieved at the 1st follow-up visit is still maintained;\n",
      "- The percentage of patients who change their therapeutic objective after 12/16 weeks of\n",
      "treatment;\n",
      "- Evolution of the PASI score (at 12/16 and 52 weeks);\n",
      "- Evolution of the DLQI score (at 12/16 and 52 weeks).\n",
      "Validated Clinical Questionnaires:\n",
      "- Dermatology Life Quality Index (DLQI)\n",
      "- PSO-TARGET QoL Component grid\n",
      "\n",
      "of satisfaction of the patient towards the therapeutic objective set by the PSO-TARGET QoL\n",
      "Component grid will be assessed using a 4 points Likert scale. The patient will also be asked\n",
      "to fill in the DLQI questionnaire. The level of satisfaction towards the therapeutic objective\n",
      "set by the PSO-TARGET QoL Component grid will be compared to the DLQI score.\n",
      "Validated Clinical Questionnaires:\n",
      "- PSO-TARGET QoL Component grid\n",
      "- DLQI\n",
      "- PASI Scores\n",
      "- Patient Benefit Index\n",
      "- 4 points Likert scale\n",
      "\n",
      " 6-10 = moderate effect on patient’s life;\n",
      " 11-20 = very large effect on patient’s life;\n",
      " 21-30 = extremely large effect on patient’s life.\n",
      "Validated Clinical Questionnaires:\n",
      "- PSO-TARGET Quality of Life Component Grid\n",
      "- Dermatology Quality of Life Index (DLQI)\n",
      "\n",
      "specifically designed for this study.\n",
      "\n",
      "Validated Clinical Questionnaires:\n",
      "• Dermatology Life Quality Index (DLQI)\n",
      "• PSO-TARGET QoL Component Grid\n",
      "\n",
      "Primary endpoint\n",
      "Sensitivity and specificity of the PSO-TARGET QoL component grid to assess the level of\n",
      "satisfaction of patient achieving the therapeutic goal, identified by himself.\n",
      "Number of patients with a DLQI 0-1\n",
      "Number of patients with a DLQI 0-1 and a positive test outcome\n",
      "Baseline characteristics\n",
      "Validated clinical questionnaires used:\n",
      "- PSO-TARGET QoL component grid\n",
      "- 4 points Likert Scale\n",
      "- DLQI scoring classes\n",
      "\n",
      "participants.\n",
      "Validated Clinical Questionnaires Used in this Text:\n",
      "- Likert scale in 4 points (“very satisfied”, “satisfied”, “unsatisfied”, “very unsatisfied”)\n",
      "- Binary logistic regression models\n",
      "- Khi-Square analysis\n",
      "- Kappa coefficient\n",
      "\n",
      "of the event.\n",
      " Probable: A reasonable temporal relationship between the medicinal product\n",
      "administration and the event, and there is a plausible explanation for the occurrence of\n",
      "the event.\n",
      " Certain: A reasonable temporal relationship between the medicinal product\n",
      "administration and the event, and there is a clear explanation for the occurrence of the\n",
      "event.\n",
      "\n",
      "Validated clinical questionnaires used in this text: Patient Information Sheet and Informed Consent Form, Diary and Questionnaires.\n",
      "\n",
      "Validated clinical questionnaires used in this text:\n",
      "- Dermatology Life Quality Index\n",
      "- Patient Benefit Index\n",
      "- Patient-Defined Outcome Questionnaire\n",
      "\n",
      " and\n",
      "efficiently\n",
      "\n",
      "Validated clinical questionnaires used in this text:\n",
      "Krueger, G., Koo, J., Lebwohl, M., Menter, A., Stern, R.S., and Rolstad, T. (2001). The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey.\n",
      "Kurd, S.K., and Gelfand, J.M. (2009). The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004.\n",
      "Lebwohl, M. (2018). Psoriasis. Annals of Internal Medicine 168, ITC49–ITC64.\n",
      "Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015). Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med 373, 1318–1328.\n",
      "Li, J., and Fine, J. (2004). On sample size for sensitivity and specificity in prospective diagnostic accuracy studies. Statistics in Medicine 23, 2537–2550.\n",
      "Lowes, M.A., Bowcock,\n",
      "\n"
     ]
    }
   ],
   "source": [
    "for answer in answers:\n",
    "    print(answer)\n",
    "    print()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.1"
  },
  "orig_nbformat": 4,
  "vscode": {
   "interpreter": {
    "hash": "12d4f619691cb3c8cdb4fc1bac3542d3bd06428ac0d8596b7ce847b27c5c0d5e"
   }
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
